$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

$ptn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000165495424001789 Filed on February 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023 Q2
Revenue	$0.00	$2.034M	$1.760M
YoY Change	-100.0%	98.18%	128.35%
Cost Of Revenue	$0.00	$97.64K	$100.0K
YoY Change	-100.0%	-1.09%	14.26%
Gross Profit	$0.00	$1.936M	$1.660M
YoY Change	-100.0%	108.74%	142.97%
Gross Profit Margin		95.2%	94.32%
Selling, General & Admin	$2.033M	$3.033M	$5.070M
YoY Change	-42.52%	-4.46%	-20.13%
% of Gross Profit		156.6%	305.42%
Research & Development	$7.160M	$5.554M	$7.410M
YoY Change	48.22%	27.17%	-0.35%
% of Gross Profit		286.82%	446.39%
Depreciation & Amortization	$85.06K	$82.06K	$80.00K
YoY Change	9.22%	17.62%	88.55%
% of Gross Profit		4.24%	4.82%
Operating Expenses	$9.218M	$861.0K	$12.48M
YoY Change	8.49%	-86.98%	-9.46%
Operating Profit	-$9.218M	$1.173M	-$10.82M
YoY Change	26.26%	-121.0%	-17.41%
Interest Expense	$1.254K	$1.605K	$100.0K
YoY Change	-63.48%	-70.75%	-70.01%
% of Operating Profit		0.14%
Other Income/Expense, Net	$0.00	$696.9K
YoY Change	-100.0%	-236.05%
Pretax Income	-$8.410M	-$7.844M	-$10.71M
YoY Change	17.66%	28.61%	-16.12%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.436M	-$7.844M	-$10.71M
YoY Change	18.02%	450.81%	-16.12%
Net Earnings / Revenue		-385.62%	-608.52%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.53	-$0.56	-$0.91
COMMON SHARES
Basic Shares Outstanding	16.14M shares	13.74M shares	11.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.01M	$9.485M	$11.00M
YoY Change	-48.99%	-55.22%	-63.26%
Cash & Equivalents	$9.224M	$4.574M	$10.98M
Short-Term Investments	$0.00	$0.00	$3.000M
Other Short-Term Assets	$254.6K	$414.0K	$1.900M
YoY Change	-88.82%	-80.54%	-1.68%
Inventory	$0.00	$0.00	$526.0K
Prepaid Expenses
Receivables	$0.00	$2.346M	$2.916M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.27M	$12.25M	$16.32M
YoY Change	-57.64%	-59.92%	-52.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$465.4K	$550.5K	$684.9K
YoY Change	-34.78%	-18.4%	27.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.92K	$56.92K	$56.92K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$1.138M	$1.309M	$1.618M
YoY Change	-16.96%	-8.13%	9.71%
TOTAL ASSETS
Total Short-Term Assets	$10.27M	$12.25M	$16.32M
Total Long-Term Assets	$1.138M	$1.309M	$1.618M
Total Assets	$11.41M	$13.55M	$17.94M
YoY Change	-55.46%	-57.61%	-50.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.443M	$1.593M	$4.304M
YoY Change	23.58%	94.25%	36.29%
Accrued Expenses	$2.365M	$5.614M	$6.511M
YoY Change	-57.28%	-7.44%	-5.3%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$73.14K	$99.91K	$100.0K
YoY Change	-30.34%	-3.58%	-0.91%
Total Short-Term Liabilities	$8.533M	$11.20M	$15.13M
YoY Change	-28.0%	-1.93%	-6.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$0.00	$11.85M	$2.083M
YoY Change	-100.0%	217.52%	-27.19%
Total Long-Term Liabilities	$0.00	$11.85M	$2.083M
YoY Change	-100.0%	217.52%	-27.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.533M	$11.20M	$15.13M
Total Long-Term Liabilities	$0.00	$11.85M	$2.083M
Total Liabilities	$9.827M	$24.52M	$17.81M
YoY Change	-38.64%	56.82%	-10.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$433.5M	-$425.1M	-$415.5M
YoY Change	7.09%	6.89%	7.1%
Common Stock	$161.4K	$143.1K	$116.6K
YoY Change	44.69%	38.15%	25.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.579M	-$11.38M	$134.1K
YoY Change
Total Liabilities & Shareholders Equity	$11.41M	$13.55M	$17.94M
YoY Change	-55.46%	-57.61%	-50.27%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023 Q2
OPERATING ACTIVITIES
Net Income	-$8.436M	-$7.844M	-$10.71M
YoY Change	18.02%	450.81%	-16.12%
Depreciation, Depletion And Amortization	$85.06K	$82.06K	$80.00K
YoY Change	9.22%	17.62%	88.55%
Cash From Operating Activities	-$8.607M	-$10.47M	-$9.610M
YoY Change	511.15%	18.68%	24.5%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$37.62K	$50.00K
YoY Change	-100.0%	-69.52%	-234.73%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$9.503M	-$2.990M
YoY Change
Cash From Investing Activities	$0.00	$9.465M	-$3.050M
YoY Change	-100.0%	-7768.54%	8118.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.136M	4.972M	1.010M
YoY Change	-36181.16%	-44.37%	-4237.65%
NET CHANGE
Cash From Operating Activities	-8.607M	-10.47M	-9.610M
Cash From Investing Activities	0.000	9.465M	-3.050M
Cash From Financing Activities	9.136M	4.972M	1.010M
Net Change In Cash	528.8K	3.966M	-11.65M
YoY Change	-134.11%	-43968.03%	49.74%
FREE CASH FLOW
Cash From Operating Activities	-$8.607M	-$10.47M	-$9.610M
Capital Expenditures	$0.00	$37.62K	$50.00K
Free Cash Flow	-$8.607M	-$10.51M	-$9.660M
YoY Change	464.32%	17.47%	25.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9485252	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11199403	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9224056	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	8463019	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	526000	usd
CY2017Q4	us-gaap	Payments For Restructuring PaymentsForRestructuring	500000	usd
CY2017Q4	ptn	Taxexpenses taxexpenses	82500	usd
CY2017Q4	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	3000000	usd
CY2023Q2	ptn	Total Carrying Value TotalCarryingValue	8782108	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	526000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2023Q4	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	136761	usd
CY2023Q2	ptn	Other Research Related Expenses OtherResearchRelatedExpenses	121121	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	188623	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	339258	usd
CY2023Q4	ptn	Personal Cost PersonalCost	0	usd
CY2023Q2	ptn	Personal Cost PersonalCost	1563847	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	260054	usd
CY2023Q4	ptn	Tota Acrrued Liabilities TotaAcrruedLiabilities	5614247	usd
CY2023Q2	ptn	Tota Acrrued Liabilities TotaAcrruedLiabilities	6511059	usd
CY2023Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	5188100	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3528050	usd
CY2023Q4	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	1106700	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3856800	usd
CY2023Q2	ptn	Accrued Other Long Term Liabilities AccruedOtherLongTermLiabilities	2083200	usd
CY2023Q4	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	0	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000911216
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	876101	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11656714	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14305137	shares
	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	1115765	usd
CY2022Q4	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities	0	usd
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	344180	shares
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	7823482	usd
CY2023Q4	ptn	Equity Gross Proceeds Shares EquityGrossProceedsShares	0	shares
	ptn	Equity Fees Shares EquityFeesShares	0	shares
CY2023Q4	ptn	Equity Fees Shares EquityFeesShares	0	shares
CY2023Q4	ptn	Equity Net Proceeds Shares EquityNetProceedsShares	0	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-15543
	dei	Entity Registrant Name EntityRegistrantName	PALATIN TECHNOLOGIES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4078884
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4B Cedar Brook Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranbury
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08512
	dei	City Area Code CityAreaCode	609
	dei	Local Phone Number LocalPhoneNumber	495‑2200
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	PTN
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16136640	shares
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9485252	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7989582	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2992890	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2346163	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2915760	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	526000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	413954	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1897281	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	12245369	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	16321513	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	550465	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	684910	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	702003	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56916	usd
CY2023Q4	us-gaap	Assets Assets	13554753	usd
CY2023Q2	us-gaap	Assets Assets	17939440	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1593476	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4303527	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5614247	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6683142	usd
CY2023Q4	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	7823482	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6511059	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	363718	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	354052	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	99912	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	106392	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3528050	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3856800	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11199403	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	15131830	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	357744	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	544323	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	46014	usd
CY2023Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	1106700	usd
CY2023Q2	us-gaap	Other Long Term Debt OtherLongTermDebt	2083200	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11852232	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1850544	usd
CY2023Q4	us-gaap	Liabilities Liabilities	24516079	usd
CY2023Q2	us-gaap	Liabilities Liabilities	19655911	usd
CY2023Q4	ptn	Contingently Redeemable Warrants ContingentlyRedeemableWarrants	423100	usd
CY2023Q2	ptn	Contingently Redeemable Warrants ContingentlyRedeemableWarrants	263400	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	40	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	40	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14305137	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11656714	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	143051	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	116567	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	413552953	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	409933959	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-425080470	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-412030437	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11384426	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1979871	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13554753	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17939440	usd
CY2023Q4	us-gaap	Revenues Revenues	2034113	usd
CY2022Q4	us-gaap	Revenues Revenues	1026416	usd
	us-gaap	Revenues Revenues	4140090	usd
	us-gaap	Revenues Revenues	1896070	usd
CY2023Q4	us-gaap	Cost Of Revenue CostOfRevenue	97637	usd
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	98707	usd
	us-gaap	Cost Of Revenue CostOfRevenue	97637	usd
	us-gaap	Cost Of Revenue CostOfRevenue	185203	usd
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5554200	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4367538	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10568830	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10394569	usd
CY2023Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3032613	usd
CY2022Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3174344	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6232857	usd
CY2022Q4	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	7823482	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023Q4	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	0	usd
CY2022Q4	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	-1027322	usd
	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	0	usd
	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	-1027322	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	860968	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	6613267	usd
	us-gaap	Operating Expenses OperatingExpenses	9075842	usd
	us-gaap	Operating Expenses OperatingExpenses	16235592	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	1173145	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5586851	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4935752	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14339522	usd
CY2023Q4	us-gaap	Investment Income Net InvestmentIncomeNet	62026	usd
CY2022Q4	us-gaap	Investment Income Net InvestmentIncomeNet	186473	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	133656	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	274962	usd
CY2023Q4	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-306697	usd
CY2022Q4	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-693231	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-146947	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-274855	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	1605	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	5487	usd
	us-gaap	Interest Expense InterestExpense	12487	usd
	us-gaap	Interest Expense InterestExpense	15089	usd
CY2023Q4	us-gaap	Other Expenses OtherExpenses	696912	usd
CY2022Q4	us-gaap	Other Expenses OtherExpenses	1115765	usd
	us-gaap	Other Expenses OtherExpenses	696912	usd
	us-gaap	Other Expenses OtherExpenses	1115765	usd
CY2023Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-8073991	usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	5247308	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-7391591	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	5247308	usd
CY2023Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9017179	usd
CY2022Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3619298	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8114281	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4116561	usd
CY2023Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7844034	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1967553	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13050033	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10222961	usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4674999	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4674999	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-7844034	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	2707446	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13050033	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5547962	usd
CY2023Q4	ptn	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.56
CY2022Q4	ptn	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	0.25
	ptn	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.99
	ptn	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.54
CY2023Q4	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	14097757	shares
CY2022Q4	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	10802863	shares
	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	13134228	shares
	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	10215616	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6320566	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	549971	usd
CY2023Q4	ptn	Conversion Of Liability Classified Warrants Upon Warrant Exerciese Amount ConversionOfLiabilityClassifiedWarrantsUponWarrantExercieseAmount	2389903	usd
CY2023Q4	ptn	Reclassification Of Contingently Redeemable Warrants ReclassificationOfContingentlyRedeemableWarrants	-159700	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-7844034	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11384426	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1979871	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	940307	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-56401	usd
	ptn	Sale Of Common Stock And Warrants Net Of Costs Amount SaleOfCommonStockAndWarrantsNetOfCostsAmount	531369	usd
	ptn	Conversion Of Liability Classified Warrants Upon Warrant Exercise Amount ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount	2389903	usd
	ptn	Reclassification Of Contingently Redeemable Warrants ReclassificationOfContingentlyRedeemableWarrants	-159700	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13050033	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11384426	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8449344	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	618704	usd
CY2022Q4	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-146062	usd
CY2022Q4	ptn	Redemption Of Convertible Series B Series C Preferred Stock Amount RedemptionOfConvertibleSeriesBSeriesCPreferredStockAmount	0	usd
CY2022Q4	ptn	Sale Of Common Stock And Warrants Net Of Costs Amount SaleOfCommonStockAndWarrantsNetOfCostsAmount	165354	usd
CY2022Q4	ptn	Reclassification Of Conginently Redeemable Warrants ReclassificationOfConginentlyRedeemableWarrants	-263400	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	2707446	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11531386	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16267875	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1055581	usd
	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-146062	usd
	ptn	Redemption Of Convertible Series B Series C Preferred Stock Amount RedemptionOfConvertibleSeriesBSeriesCPreferredStockAmount	0	usd
	ptn	Sale Of Common Stock And Warrants Net Of Costs Amount SaleOfCommonStockAndWarrantsNetOfCostsAmount	165354	usd
	ptn	Reverse Stock Split Fractional Shares Amount ReverseStockSplitFractionalSharesAmount	0	usd
	ptn	Reclassification Of Conginently Redeemable Warrants ReclassificationOfConginentlyRedeemableWarrants	-263400	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5547962	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11531386	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13050033	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5547962	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	172060	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	129403	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	174098	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	184736	usd
	ptn	Unrealized Foreign Currency Transaction Gain UnrealizedForeignCurrencyTransactionGain	146947	usd
	ptn	Unrealized Foreign Currency Transaction Gain UnrealizedForeignCurrencyTransactionGain	274855	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	940307	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1055581	usd
	ptn	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	7391591	usd
	ptn	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	-5247308	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-7823482	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	0	usd
	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	-1027322	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	569597	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-26970	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-4674999	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1047164	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-194776	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1154355	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	185203	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2710051	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2373682	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-896812	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-809395	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-176913	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-184629	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1012197	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16382079	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18257265	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2992890	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
	ptn	Proceeds From Sale Of Business ProceedsFromSaleOfBusiness	9500000	usd
	ptn	Proceeds From Sale Of Business ProceedsFromSaleOfBusiness	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37615	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	264656	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12455275	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-264656	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	56401	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	146062	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5531266	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9961462	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	52494	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	49794	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	103	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5422474	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9765606	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1495670	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8756315	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7989582	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29939154	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9485252	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21182839	usd
	us-gaap	Interest Paid Net InterestPaidNet	12487	usd
	us-gaap	Interest Paid Net InterestPaidNet	15089	usd
	ptn	Conversion Of Liability Classified Warrants Upon Warrant Exercise ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise	2389903	usd
	ptn	Conversion Of Liability Classified Warrants Upon Warrant Exercise ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise	0	usd
CY2023Q4	ptn	Retained Earning Accumulated Deficit RetainedEarningAccumulatedDeficit	425080470	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-7844034	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13050033	usd
	ptn	Description Of Sales Based Payments DescriptionOfSalesBasedPayments	The Company may receive contingent, sales-based milestone payments of up to $159 million on sales of Vyleesi by Cosette and its licensees
	ptn	Payments To Sales Based Milestone Payments PaymentsToSalesBasedMilestonePayments	159000000	usd
CY2023Q4	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	7823482	usd
CY2023Q2	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	816750	usd
CY2023Q2	us-gaap	Market Risk Benefit Liability Amount MarketRiskBenefitLiabilityAmount	1850544	usd
CY2023Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	263400	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5619090	usd
CY2023Q2	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	3505146	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	5247308	usd
CY2022Q4	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	1115765	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	852345	usd
	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities	852345	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Use of Estimates</em> – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q2	ptn	Money Market Accounts And Treasury Bills MoneyMarketAccountsAndTreasuryBills	5789218	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Credit Risk</em> – Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and accounts receivable. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company. Currently, product revenues and related accounts receivable are generated primarily from one specialty pharmacy.</p>
	us-gaap	Accounts Receivable Purchase AccountsReceivablePurchase	171000000	usd
	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	9500000	usd
	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1	2500000	usd
CY2023Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6595422	shares
CY2022Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3429015	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	279700	shares
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	121482	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	596374	usd
	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	1027322	usd
CY2017Q3	us-gaap	Increase Decrease In Deferred Revenue And Customer Advances And Deposits IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits	4500000	usd
CY2017Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	5000000	usd
CY2017Q3	ptn	Upfront Payment Of Less UpfrontPaymentOfLess	500000	usd
CY2017Q3	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	7500000	usd
CY2017Q4	us-gaap	Officers Compensation OfficersCompensation	417500	usd
CY2023Q4	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	126188	usd
CY2023Q2	ptn	Prepaid Clinical Study Costs PrepaidClinicalStudyCosts	141512	usd
CY2023Q4	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	166284	usd
CY2023Q2	ptn	Prepaid Insurance Premiums PrepaidInsurancePremiums	342645	usd
CY2023Q4	ptn	Vyleesi Contractual Advances VyleesiContractualAdvances	0	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	413954	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1897281	usd
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	8463019	usd
CY2023Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	2808598	usd
CY2023Q2	ptn	Cash Equivalents Treasury Bill At Carrying Value CashEquivalentsTreasuryBillAtCarryingValue	2980620	usd
CY2023Q2	ptn	Marketable Securities Treasury Bill At Carrying Value MarketableSecuritiesTreasuryBillAtCarryingValue	2992890	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M2D
	ptn	Equity Gross Proceeds Shares EquityGrossProceedsShares	217027	shares
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	547803	usd
	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	16434	usd
CY2023Q4	ptn	Equity Expenses Proceeds EquityExpensesProceeds	0	usd
	ptn	Equity Expenses Proceeds EquityExpensesProceeds	0	usd
CY2023Q4	ptn	Equity Net Proceeds Proceeds EquityNetProceedsProceeds	0	usd
CY2023Q4	ptn	Clinical Study Costs ClinicalStudyCosts	2227530	usd
CY2023Q2	ptn	Clinical Study Costs ClinicalStudyCosts	2960126	usd
CY2023Q4	ptn	Accrued Selling Expenses AccruedSellingExpenses	2983090	usd
CY2023Q2	ptn	Accrued Selling Expenses AccruedSellingExpenses	1266653	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	78243	usd
	us-gaap	Proceeds From Grantors ProceedsFromGrantors	15000000	usd
	ptn	Voting Of Shares Description VotingOfSharesDescription	The holders of Series C Preferred Stock were entitled to 20,000 votes per share
CY2023Q4	ptn	Cash Available For Distributions Additional CashAvailableForDistributionsAdditional	100	usd
CY2023Q4	ptn	Description Of Securities Purchases DescriptionOfSecuritiesPurchases	1,325,000 shares of common stock, $0.01 par value per share (the “October 2023 Shares”), of the Company and (ii) pre-funded warrants (the “October 2023 Pre-Funded Warrants”) to purchase up to 1,033,491 shares of the Company’s common stock (the “October 2023 Pre-Funded Warrant Shares”). The October 2023 Purchase Agreement also provides that the Company will issue unregistered warrants (the “October 2023 Private Warrants”) to purchase up to 2,358,491 shares of the Company’s common stock (the “October 2023 Private Warrant Shares”) in a concurrent private placement (the “October 2023 Private Offering” and together with the October 2023 RD Offering, the “October 2023 Offering”). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.12
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
	ptn	Warrant To Purchase Common Stock WarrantToPurchaseCommonStock	1033491	shares
	us-gaap	Costs And Expenses CostsAndExpenses	4573948	usd
CY2022Q4	ptn	Description Of Securities Purchases DescriptionOfSecuritiesPurchases	1,020,000 shares of the Company’s common stock, (ii) prefunded warrants (the “October 2022 Pre-Funded Warrants”) to purchase up to 798,182 shares of the Company’s common stock, and (iii) common stock warrants (the “October 2002 Common Warrants”) to purchase up to 1,818,182 shares of the Company’s common stock. Each share of common stock was offered with one accompanying October 2022 Common Warrant with a combined offering price of $5.50. Each October 2022 Pre-Funded Warrant was offered with one accompanying October 2022 Common Warrant with a combined offering price of $5.4999
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.83
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2023	ptn	Warrant To Purchase Common Stock WarrantToPurchaseCommonStock	798182	shares
CY2023Q4	us-gaap	Costs And Expenses CostsAndExpenses	9109117000000	usd
	ptn	Description Of Commission DescriptionOfCommission	The Company pays Canaccord 3.0% of the gross proceeds as a commission
CY2023Q4	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	0	usd
	ptn	Equity Net Proceeds Shares EquityNetProceedsShares	217027	shares
	ptn	Equity Net Proceeds Proceeds EquityNetProceedsProceeds	531369	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M20D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8574	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8235	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0387	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0416	pure
CY2023Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	205223	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	410540	usd
CY2022Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	121584	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	382541	usd
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance	1550600	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance	8.27
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P8Y4M24D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance	1550600	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance	8.27
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
	ptn	Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding And Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue	1215066	usd
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance	559459	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice	14.17
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumberEndingBalance	991141	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice	4.94
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y10M24D
	ptn	Share Based Compensation Arrangement By Shares Based Payment Award Options Vested And Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue	1215066	usd
	ptn	Weighted Average Unrecogized Compensation Cost WeightedAverageUnrecogizedCompensationCost	P48M
CY2023Q4	ptn	Unvested Performance Based Stock Options Granted To Executive Officers And Other Employees UnvestedPerformanceBasedStockOptionsGrantedToExecutiveOfficersAndOtherEmployees	318813	shares
CY2023Q4	ptn	Unvested Performance Based Stock Options Granted UnvestedPerformanceBasedStockOptionsGranted	57999	shares
CY2020Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	87303	usd
CY2021Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	95167	usd
CY2022Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	60566	usd
CY2023Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	238838	usd
CY2023Q4	us-gaap	Restricted Stock Expense RestrictedStockExpense	185019	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	370038	usd
CY2022Q4	us-gaap	Restricted Stock Expense RestrictedStockExpense	233700	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	409620	usd
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityBeginningBalance	987521	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	2302	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired	-18000	shares
	ptn	Restricted Stock Vested In Period RestrictedStockVestedInPeriod	-98372	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEndingBalance	868847	shares
CY2023Q4	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Veste Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVesteOutstandingNumber	279700	shares
	ptn	Sale Value Of The Tax Benefits To Unaffiliated SaleValueOfTheTaxBenefitsToUnaffiliated	0.80	pure
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4674999	usd
CY2024Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	1831503	shares
	us-gaap	Payments For Fees PaymentsForFees	10000006	usd
	ptn	Offering Expenses OfferingExpenses	9224056	usd

Files In Submission

Name	View Source	Status
0001654954-24-001789-index-headers.html	Edgar Link	pending
0001654954-24-001789-index.html	Edgar Link	pending
0001654954-24-001789.txt	Edgar Link	pending
0001654954-24-001789-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptn-20231231.xsd	Edgar Link	pending
ptn_10q.htm	Edgar Link	pending
ptn_10qimg19.jpg	Edgar Link	pending
ptn_10qimg20.jpg	Edgar Link	pending
ptn_ex102.htm	Edgar Link	pending
ptn_ex311.htm	Edgar Link	pending
ptn_ex312.htm	Edgar Link	pending
ptn_ex321.htm	Edgar Link	pending
ptn_ex322.htm	Edgar Link	pending
ptn_ex43.htm	Edgar Link	pending
ptn_ex44.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
ptn-20231231_cal.xml	Edgar Link	unprocessable
ptn-20231231_def.xml	Edgar Link	unprocessable
ptn-20231231_lab.xml	Edgar Link	unprocessable
ptn-20231231_pre.xml	Edgar Link	unprocessable
ptn_10q_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

2024 Q1 Form 10-Q Financial Statement

#000165495424001789 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN PALATIN TECHNOLOGIES INC Stock $ptn

2024 Q1 Form 10-Q Financial Statement

#000165495424001789 Filed on February 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn